Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and rare metabolic conditions. The company advances clinical pipeline candidates targeting neurodegenerative conditions, metabolic diseases, and endocrine disorders. Principal revenues were historically generated through commercial sales of Relyvrio alongside research partnerships, licensing options, and development capital financing. Core end markets serve neurology clinical centers, neurodegenerative research institutes, endocrinology specialists, and specialty prescription patients globally. Amylyx Pharmaceuticals holds an established position in the biopharmaceutical sector for neurodegenerative disease therapeutic research. The corporation is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
6 of the funds FundTelligence covers report a position in Amylyx Pharmaceuticals.
- Legal name
- Amylyx Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Amylyx Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 2.4 % (full portfolio disclosed, September 2026)
- JPM US Small Cap Growth Fund — JPM · 0.57 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.24 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.09 % (full portfolio disclosed, September 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)